| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 19.55 | 10.2% | 56.5% |
| Total Income | 19.55 | 10.2% | 56.5% |
| Expenditure | 52.49 | 10.6% | 31.6% |
| PBT | -32.90 | 80.0% | 22.7% |
| Net Profit | -34.69 | 3.7% | 28.8% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.09 | 0.0% | 28.6% |
Standard BioTools Reports Q3 2025 Financial Results
04 May 2026 · 4 May, 8:14 am
Summary
Standard BioTools Inc. announced financial results for the quarter ended September 30, 2025. Third quarter revenue from continuing operations was $19.6 million, down 11% year-over-year. The company implemented a restructuring plan expected to deliver over $40 million in annualized cost savings. For fiscal year 2025, the company continues to expect combined revenue in the range of $165 million to $175 million and revenue from continuing operations is expected to be in the range of $78 million to $83 million.
Key Highlights
- 1
Third quarter 2025 total combined company revenue was $46.2 million.
- 2
Revenue from continuing operations was $19.6 million for Q3 2025.
- 3
The company implemented a restructuring plan expected to deliver over $40 million in annualized cost savings.
- 4
Standard BioTools expects approximately $550 million in cash & cash equivalents at close of transaction with Illumina in first half of 2026.
- 5
Cash & cash equivalents were $217.0 million as of September 30, 2025.
- 6
The company continues to expect combined revenue in the range of $165 million to $175 million for fiscal year 2025.
- 7
Revenue from continuing operations is expected to be in the range of $78 million to $83 million for fiscal year 2025.
Management Comments
Michael Egholm
PhD
“The third quarter marked another period of solid execution as we sharpen our focus and position Standard BioTools for the next stage. Our commercial team delivered consistent overall performance amid a still-evolving macro environment, and with cost savings initiatives beginning to take hold, we are simplifying operations, increasing productivity and driving the go-forward business toward profitability expected in 2026. Combined with a strong balance sheet at quarter end and the significant cash injection expected from the pending Illumina transaction, we are well positioned to expand our portfolio through strategic M&A that we believe will fuel growth and deliver long-term value for our shareholders.”
Alex Kim
“Given the current operating environment, these decisions were important to keep our organization lean, focused and positioned to emerge stronger tomorrow than we are today. I want to sincerely thank our departing colleagues for their contributions as we take these steps to secure the long-term success of Standard BioTools – delivering innovative solutions to our customers as they advance science and improve human health.”
Informational and educational content only. Not investment advice.